Symbols / MDXG Stock $3.28 -1.06% MiMedx Group, Inc.
MDXG (Stock) Chart
About
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.
Stock Fundamentals
Scroll to Statements| Market Cap | 486.56M | Enterprise Value | 348.17M | Income | 48.58M | Sales | 418.63M | Book/sh | 1.73 | Cash/sh | 1.12 |
| Dividend Yield | — | Payout | 0.00% | Employees | 808 | IPO | — | P/E | 10.23 | Forward P/E | 18.71 |
| PEG | 2.88 | P/S | 1.16 | P/B | 1.89 | P/C | — | EV/EBITDA | 4.42 | EV/Sales | 0.83 |
| Quick Ratio | 3.76 | Current Ratio | 4.32 | Debt/Eq | 8.78 | LT Debt/Eq | — | EPS (ttm) | 0.32 | EPS next Y | 0.17 |
| EPS Growth | 99.50% | Revenue Growth | 27.10% | Earnings | 2026-04-29 | ROA | 13.17% | ROE | 21.61% | ROIC | — |
| Gross Margin | 82.56% | Oper. Margin | 17.85% | Profit Margin | 11.60% | Shs Outstand | 148.57M | Shs Float | 117.61M | Short Float | 6.46% |
| Short Ratio | 7.32 | Short Interest | — | 52W High | 7.99 | 52W Low | 3.19 | Beta | 1.65 | Avg Volume | 1.16M |
| Volume | 97.60K | Target Price | $8.00 | Recom | Strong_buy | Prev Close | $3.31 | Price | $3.27 | Change | -1.06% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-20 | main | Citizens | Market Outperform → Market Outperform | $7 |
| 2026-04-17 | main | Craig-Hallum | Buy → Buy | $7 |
| 2026-02-23 | init | Citizens | — → Market Outperform | $10 |
| 2026-02-17 | main | Cantor Fitzgerald | Overweight → Overweight | $8 |
| 2026-01-20 | main | Lake Street | Buy → Buy | $10 |
| 2025-12-17 | main | Mizuho | Outperform → Outperform | $10 |
| 2025-07-31 | main | Cantor Fitzgerald | Overweight → Overweight | $12 |
| 2025-07-15 | reit | Cantor Fitzgerald | Overweight → Overweight | $11 |
| 2025-02-27 | reit | Cantor Fitzgerald | Overweight → Overweight | $13 |
| 2024-08-01 | reit | Cantor Fitzgerald | Overweight → Overweight | $11 |
| 2024-08-01 | main | Craig-Hallum | Buy → Buy | $12 |
| 2024-07-02 | init | Cantor Fitzgerald | — → Overweight | $11 |
| 2024-05-01 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-03-07 | init | Lake Street | — → Buy | $12 |
| 2024-03-01 | main | Mizuho | Buy → Buy | $14 |
| 2023-10-31 | main | Mizuho | Buy → Buy | $12 |
| 2023-10-27 | init | Craig-Hallum | — → Buy | $12 |
| 2023-08-02 | main | Mizuho | Buy → Buy | $12 |
| 2023-08-02 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-06-21 | main | HC Wainwright & Co. | Buy → Buy | $8 |
- Is MiMedx Group (MDXG) stock trading at a premium valuation | MiMedx Group Inc posts 16.7 pct EPS beat vs ests - Profit Guidance - UBND thành phố Hải Phòng hu, 23 Apr 2026 09
- Is MiMedx Group (MDXG) stock hitting resistance today (Dips) 2026-04-20 - Momentum Surge - Cổng thông tin điện tử tỉnh Tây Ninh ue, 21 Apr 2026 04
- MIMEDX posts quarterly results April 29, with webcast after close - Stock Titan Wed, 22 Apr 2026 12
- How The MiMedx Group (MDXG) Story Is Shifting With Medicare And Analyst Revisions - Yahoo Finance Sun, 05 Apr 2026 07
- MDXG Stock Price, Quote & Chart | MIMEDX GROUP INC (NASDAQ:MDXG) - ChartMill Fri, 17 Apr 2026 07
- $MDXG stock is down 13% today. Here's what we see in our data. - Quiver Quantitative hu, 16 Apr 2026 15
- MDXG Maintained by Citizens -- Price Target Lowered to $7.00 - GuruFocus Mon, 20 Apr 2026 13
- 5 Most Undervalued Healthcare Stocks to Buy Now - Insider Monkey hu, 23 Apr 2026 10
- MiMedx Group, Inc (MDXG) Stock Analysis: Exploring an 81% Potential Upside in the Biotech Sector - DirectorsTalk Interviews ue, 24 Feb 2026 08
- Would buying MiMedx Group (MDXG) stock now make sense (Underperforming) 2026-04-20 - Institutional Grade Picks - Cổng thông tin điện tử tỉnh Lào Cai Mon, 20 Apr 2026 06
- Earnings Preview: MiMedx (MDXG) Q1 Earnings Expected to Decline - Yahoo Finance Wed, 22 Apr 2026 14
- Is MiMedx Group (MDXG) Stock Good for Short Term | Price at $3.87, Down 2.49% - Crowd Trend Signals - Xã Vĩnh Công hu, 09 Apr 2026 07
- MIMEDX cuts $40M in annual costs as wound-care recovery lags - Stock Titan hu, 16 Apr 2026 12
- How The MiMedx Group (MDXG) Investment Story Is Shifting On Reimbursement Risk And Recovery Hopes - Yahoo Finance Mon, 09 Mar 2026 07
- Are short sellers targeting MiMedx Group (MDXG) Stock | Price at $3.90, Up 0.65% - Community Volume Signals - UBND thành phố Hải Phòng Mon, 13 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
418.63
+19.99%
|
348.88
+8.52%
|
321.48
+20.03%
|
267.84
|
| Operating Revenue |
|
418.63
+19.99%
|
348.88
+8.52%
|
321.48
+20.03%
|
267.84
|
| Cost Of Revenue |
|
73.01
+21.54%
|
60.07
+9.96%
|
54.63
+13.08%
|
48.32
|
| Reconciled Cost Of Revenue |
|
58.57
+6.89%
|
54.80
+5.44%
|
51.97
+15.56%
|
44.97
|
| Gross Profit |
|
345.62
+19.67%
|
288.81
+8.23%
|
266.84
+21.55%
|
219.53
|
| Operating Expense |
|
281.73
+22.76%
|
229.50
-0.10%
|
229.73
-1.93%
|
234.25
|
| Research And Development |
|
15.10
+22.33%
|
12.34
-2.56%
|
12.66
-0.28%
|
12.70
|
| Selling General And Administration |
|
266.19
+18.26%
|
225.09
+6.61%
|
211.12
+1.17%
|
208.67
|
| Other Operating Expenses |
|
—
|
-8.70
-268.04%
|
5.18
-57.49%
|
12.18
|
| Total Expenses |
|
354.74
+22.51%
|
289.57
+1.83%
|
284.36
+0.63%
|
282.57
|
| Operating Income |
|
63.89
+7.72%
|
59.31
+59.80%
|
37.12
+352.03%
|
-14.73
|
| Total Operating Income As Reported |
|
63.89
+8.53%
|
58.87
+58.60%
|
37.12
+352.03%
|
-14.73
|
| EBITDA |
|
78.77
+20.53%
|
65.35
+61.19%
|
40.54
+479.44%
|
-10.69
|
| Normalized EBITDA |
|
78.77
+19.71%
|
65.80
+62.29%
|
40.54
+479.44%
|
-10.69
|
| Reconciled Depreciation |
|
14.88
+146.33%
|
6.04
+76.28%
|
3.43
-15.30%
|
4.05
|
| EBIT |
|
63.89
+7.72%
|
59.31
+59.80%
|
37.12
+351.96%
|
-14.73
|
| Total Unusual Items |
|
0.00
+100.00%
|
-0.45
|
0.00
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
0.00
+100.00%
|
-0.45
|
0.00
|
0.00
|
| Special Income Charges |
|
0.00
+100.00%
|
-0.45
|
0.00
|
0.00
|
| Impairment Of Capital Assets |
|
0.00
-100.00%
|
0.45
|
0.00
|
0.00
|
| Net Income |
|
48.58
+14.52%
|
42.42
-27.15%
|
58.23
+292.83%
|
-30.20
|
| Pretax Income |
|
66.26
+15.65%
|
57.29
+87.03%
|
30.63
+255.13%
|
-19.75
|
| Net Non Operating Interest Income Expense |
|
2.93
+391.55%
|
-1.01
+84.42%
|
-6.46
-28.73%
|
-5.02
|
| Interest Expense Non Operating |
|
—
|
1.01
-84.42%
|
6.46
+28.73%
|
5.02
|
| Net Interest Income |
|
2.93
+391.55%
|
-1.01
+84.42%
|
-6.46
-28.73%
|
-5.02
|
| Interest Expense |
|
—
|
1.01
-84.42%
|
6.46
+28.73%
|
5.02
|
| Other Income Expense |
|
-0.56
+44.81%
|
-1.01
-3788.46%
|
-0.03
-550.00%
|
-0.00
|
| Other Non Operating Income Expenses |
|
-0.56
+1.24%
|
-0.56
-2073.08%
|
-0.03
-550.00%
|
-0.00
|
| Tax Provision |
|
17.68
+15.61%
|
15.30
+141.56%
|
-36.81
-17966.99%
|
0.21
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+27.14%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
+100.00%
|
-0.12
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
48.58
+14.52%
|
42.42
-27.15%
|
58.23
+292.83%
|
-30.20
|
| Net Income From Continuing Operation Net Minority Interest |
|
48.58
+15.67%
|
42.00
-37.72%
|
67.44
+437.99%
|
-19.95
|
| Net Income From Continuing And Discontinued Operation |
|
48.58
+14.52%
|
42.42
-27.15%
|
58.23
+292.83%
|
-30.20
|
| Net Income Continuous Operations |
|
48.58
+15.67%
|
42.00
-37.72%
|
67.44
+437.99%
|
-19.95
|
| Net Income Discontinuous Operations |
|
0.00
-100.00%
|
0.42
+104.57%
|
-9.21
+10.08%
|
-10.24
|
| Normalized Income |
|
48.58
+14.77%
|
42.32
-37.24%
|
67.44
+437.99%
|
-19.95
|
| Net Income Common Stockholders |
|
48.58
+14.52%
|
42.42
-8.94%
|
46.59
+226.67%
|
-36.78
|
| Otherunder Preferred Stock Dividend |
|
0.00
|
0.00
-100.00%
|
4.89
|
0.00
|
| Diluted EPS |
|
0.32
+14.29%
|
0.28
-24.32%
|
0.37
+212.12%
|
-0.33
|
| Basic EPS |
|
0.33
+13.79%
|
0.29
-27.50%
|
0.40
+221.21%
|
-0.33
|
| Basic Average Shares |
|
147.79
+0.55%
|
146.98
+26.17%
|
116.50
+3.18%
|
112.91
|
| Diluted Average Shares |
|
149.72
+0.45%
|
149.05
+2.11%
|
145.96
+29.27%
|
112.91
|
| Diluted NI Availto Com Stockholders |
|
48.58
+14.52%
|
42.42
-8.94%
|
46.59
+226.67%
|
-36.78
|
| Amortization |
|
0.44
-42.61%
|
0.77
+0.39%
|
0.76
+8.70%
|
0.70
|
| Amortization Of Intangibles Income Statement |
|
0.44
-42.61%
|
0.77
+0.39%
|
0.76
+8.70%
|
0.70
|
| Depreciation Amortization Depletion Income Statement |
|
0.44
-42.61%
|
0.77
+0.39%
|
0.76
+8.70%
|
0.70
|
| Depreciation And Amortization In Income Statement |
|
0.44
-42.61%
|
0.77
+0.39%
|
0.76
+8.70%
|
0.70
|
| Preferred Stock Dividends |
|
—
|
—
|
6.75
+2.63%
|
6.58
|
| Total Other Finance Cost |
|
-2.93
-391.55%
|
1.01
-84.42%
|
6.46
|
—
|
| Line Item | Trend | 2023-12-31 | 2021-12-31 |
|---|---|---|---|
| Total Assets |
|
239.05
|
—
|
| Current Assets |
|
164.26
|
—
|
| Cash Cash Equivalents And Short Term Investments |
|
82.00
|
—
|
| Cash And Cash Equivalents |
|
82.00
|
—
|
| Receivables |
|
53.87
|
—
|
| Accounts Receivable |
|
53.87
|
—
|
| Gross Accounts Receivable |
|
57.02
|
—
|
| Allowance For Doubtful Accounts Receivable |
|
-3.14
|
—
|
| Taxes Receivable |
|
—
|
0.74
|
| Inventory |
|
21.02
|
—
|
| Raw Materials |
|
0.82
|
—
|
| Work In Process |
|
8.52
|
—
|
| Finished Goods |
|
11.68
|
—
|
| Prepaid Assets |
|
5.62
-8.49%
|
6.15
|
| Assets Held For Sale Current |
|
0.00
|
—
|
| Other Current Assets |
|
1.75
|
—
|
| Total Non Current Assets |
|
74.79
|
—
|
| Net PPE |
|
9.11
|
—
|
| Gross PPE |
|
29.13
|
—
|
| Accumulated Depreciation |
|
-20.03
|
—
|
| Properties |
|
0.00
|
—
|
| Machinery Furniture Equipment |
|
1.99
|
—
|
| Construction In Progress |
|
1.79
|
—
|
| Other Properties |
|
17.21
|
—
|
| Leases |
|
8.14
|
—
|
| Goodwill And Other Intangible Assets |
|
24.70
|
—
|
| Goodwill |
|
19.44
|
—
|
| Other Intangible Assets |
|
5.26
|
—
|
| Non Current Deferred Assets |
|
40.78
|
—
|
| Non Current Deferred Taxes Assets |
|
40.78
|
—
|
| Other Non Current Assets |
|
0.20
|
—
|
| Total Liabilities Net Minority Interest |
|
96.33
|
—
|
| Current Liabilities |
|
46.01
|
—
|
| Payables And Accrued Expenses |
|
18.41
|
—
|
| Payables |
|
9.05
|
—
|
| Accounts Payable |
|
9.05
|
—
|
| Other Payable |
|
—
|
—
|
| Current Accrued Expenses |
|
9.36
|
—
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
22.35
|
—
|
| Current Debt And Capital Lease Obligation |
|
1.00
|
—
|
| Current Debt |
|
1.00
|
—
|
| Other Current Borrowings |
|
1.00
|
—
|
| Other Current Liabilities |
|
4.25
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
50.32
|
—
|
| Long Term Debt And Capital Lease Obligation |
|
48.10
|
—
|
| Long Term Debt |
|
48.10
|
—
|
| Other Non Current Liabilities |
|
2.22
|
—
|
| Preferred Securities Outside Stock Equity |
|
0.00
-100.00%
|
92.49
|
| Stockholders Equity |
|
142.72
|
—
|
| Common Stock Equity |
|
142.72
|
—
|
| Capital Stock |
|
0.15
|
—
|
| Common Stock |
|
0.15
|
—
|
| Preferred Stock |
|
—
|
0.00
|
| Share Issued |
|
146.23
|
—
|
| Ordinary Shares Number |
|
146.23
|
—
|
| Treasury Shares Number |
|
0.00
-100.00%
|
0.78
|
| Additional Paid In Capital |
|
276.25
|
—
|
| Retained Earnings |
|
-133.68
|
—
|
| Treasury Stock |
|
0.00
-100.00%
|
4.02
|
| Total Equity Gross Minority Interest |
|
142.72
|
—
|
| Total Capitalization |
|
190.82
|
—
|
| Working Capital |
|
118.25
|
—
|
| Invested Capital |
|
191.82
|
—
|
| Total Debt |
|
49.10
|
—
|
| Net Tangible Assets |
|
118.02
|
—
|
| Tangible Book Value |
|
118.02
|
—
|
| Preferred Shares Number |
|
—
|
0.10
|
| Preferred Stock Equity |
|
—
|
92.49
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
74.00
+11.79%
|
66.20
+147.24%
|
26.77
+249.64%
|
-17.89
|
| Cash Flow From Continuing Operating Activities |
|
74.00
+10.24%
|
67.13
+92.14%
|
34.94
+538.25%
|
-7.97
|
| Cash From Discontinued Operating Activities |
|
0.00
+100.00%
|
-0.93
+88.61%
|
-8.16
+17.73%
|
-9.92
|
| Net Income From Continuing Operations |
|
48.58
+15.67%
|
42.00
-37.72%
|
67.44
+437.99%
|
-19.95
|
| Depreciation Amortization Depletion |
|
14.88
+146.33%
|
6.04
+76.28%
|
3.43
-15.30%
|
4.05
|
| Depreciation |
|
—
|
2.28
-14.48%
|
2.67
-20.33%
|
3.35
|
| Amortization Cash Flow |
|
—
|
3.76
+393.70%
|
0.76
+8.70%
|
0.70
|
| Depreciation And Amortization |
|
14.88
+146.33%
|
6.04
+76.28%
|
3.43
-15.30%
|
4.05
|
| Amortization Of Intangibles |
|
—
|
3.76
+393.70%
|
0.76
+8.70%
|
0.70
|
| Other Non Cash Items |
|
1.90
+127.67%
|
-6.88
-465.66%
|
1.88
+4.44%
|
1.80
|
| Stock Based Compensation |
|
16.40
-3.17%
|
16.93
-0.15%
|
16.96
+49.71%
|
11.33
|
| Provisionand Write Offof Assets |
|
6.51
+994.96%
|
0.59
-58.94%
|
1.45
-48.62%
|
2.82
|
| Asset Impairment Charge |
|
—
|
—
|
1.45
-48.62%
|
2.82
|
| Deferred Tax |
|
8.71
-30.16%
|
12.47
+132.99%
|
-37.80
|
0.00
|
| Deferred Income Tax |
|
8.71
-30.16%
|
12.47
+132.99%
|
-37.80
|
0.00
|
| Operating Gains Losses |
|
—
|
1.40
+9240.00%
|
0.01
+188.24%
|
-0.02
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
0.01
+188.24%
|
-0.02
|
| Change In Working Capital |
|
-22.98
-322.89%
|
-5.43
+70.49%
|
-18.42
-129.80%
|
-8.01
|
| Change In Receivables |
|
-26.39
-934.25%
|
-2.55
+79.15%
|
-12.24
-106.11%
|
-5.94
|
| Changes In Account Receivables |
|
—
|
—
|
-12.24
-120.49%
|
-5.55
|
| Change In Inventory |
|
-1.53
+34.96%
|
-2.36
+69.93%
|
-7.84
-336.90%
|
-1.79
|
| Change In Prepaid Assets |
|
—
|
0.61
+314.13%
|
-0.28
+79.36%
|
-1.37
|
| Change In Payables And Accrued Expense |
|
13.48
+1833.43%
|
0.70
-22.90%
|
0.90
-32.84%
|
1.35
|
| Change In Accrued Expense |
|
11.36
+439.01%
|
2.11
+1641.32%
|
0.12
-76.13%
|
0.51
|
| Change In Payable |
|
2.12
+250.28%
|
-1.41
-280.08%
|
0.78
-6.67%
|
0.84
|
| Change In Account Payable |
|
2.12
+250.28%
|
-1.41
-280.08%
|
0.78
-6.67%
|
0.84
|
| Change In Other Working Capital |
|
0.29
+133.22%
|
-0.87
-75.05%
|
-0.50
-92.64%
|
-0.26
|
| Change In Other Current Assets |
|
-8.82
-2405.11%
|
-0.35
-128.12%
|
1.25
+475.98%
|
-0.33
|
| Change In Other Current Liabilities |
|
—
|
—
|
-0.50
-1407.89%
|
0.04
|
| Investing Cash Flow |
|
-6.89
+28.14%
|
-9.58
-344.69%
|
-2.15
+18.98%
|
-2.66
|
| Cash Flow From Continuing Investing Activities |
|
-6.89
+28.14%
|
-9.58
-344.69%
|
-2.15
+18.98%
|
-2.66
|
| Net PPE Purchase And Sale |
|
-1.03
+38.62%
|
-1.68
+15.30%
|
-1.99
-31.24%
|
-1.51
|
| Purchase Of PPE |
|
-1.03
+38.62%
|
-1.68
+15.30%
|
-1.99
-31.24%
|
-1.51
|
| Sale Of PPE |
|
—
|
—
|
0.00
-100.00%
|
0.02
|
| Capital Expenditure |
|
-1.03
+38.62%
|
-1.68
+15.30%
|
-1.99
-31.24%
|
-1.51
|
| Net Business Purchase And Sale |
|
-3.76
+52.12%
|
-7.86
|
0.00
|
0.00
|
| Purchase Of Business |
|
-3.76
+52.12%
|
-7.86
|
0.00
|
0.00
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
0.00
+100.00%
|
-1.00
|
| Purchase Of Intangibles |
|
—
|
—
|
0.00
+100.00%
|
-1.00
|
| Net Other Investing Changes |
|
-2.09
-5397.37%
|
-0.04
+77.38%
|
-0.17
+85.34%
|
-1.15
|
| Financing Cash Flow |
|
-5.41
+84.17%
|
-34.20
-299.05%
|
-8.57
-1377.59%
|
-0.58
|
| Cash Flow From Continuing Financing Activities |
|
-5.41
+84.17%
|
-34.20
-299.05%
|
-8.57
-1377.59%
|
-0.58
|
| Net Issuance Payments Of Debt |
|
-1.00
+96.85%
|
-31.72
|
0.00
|
0.00
|
| Issuance Of Debt |
|
0.00
-100.00%
|
49.78
|
0.00
|
0.00
|
| Repayment Of Debt |
|
-1.00
+98.77%
|
-81.50
|
0.00
|
0.00
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
49.78
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
-1.00
+98.77%
|
-81.50
|
0.00
|
0.00
|
| Net Long Term Debt Issuance |
|
-1.00
+96.85%
|
-31.72
|
0.00
|
0.00
|
| Net Common Stock Issuance |
|
-3.12
-18.06%
|
-2.64
|
0.00
+100.00%
|
-1.19
|
| Common Stock Payments |
|
-3.12
-18.06%
|
-2.64
|
0.00
+100.00%
|
-1.19
|
| Repurchase Of Capital Stock |
|
-3.12
-18.06%
|
-2.64
+72.24%
|
-9.52
-699.58%
|
-1.19
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
1.40
+40.12%
|
1.00
+53.15%
|
0.65
|
| Net Other Financing Charges |
|
-1.29
-4.52%
|
-1.24
-2280.77%
|
-0.05
-26.83%
|
-0.04
|
| Changes In Cash |
|
61.70
+175.27%
|
22.42
+39.66%
|
16.05
+175.95%
|
-21.13
|
| Beginning Cash Position |
|
104.42
+27.34%
|
82.00
+24.34%
|
65.95
-24.27%
|
87.08
|
| End Cash Position |
|
166.12
+59.10%
|
104.42
+27.34%
|
82.00
+24.34%
|
65.95
|
| Free Cash Flow |
|
72.97
+13.11%
|
64.52
+160.27%
|
24.79
+227.73%
|
-19.41
|
| Interest Paid Supplemental Data |
|
—
|
2.70
-55.29%
|
6.03
+32.06%
|
4.57
|
| Income Tax Paid Supplemental Data |
|
—
|
3.25
|
—
|
0.18
|
| Issuance Of Capital Stock |
|
—
|
—
|
—
|
0.00
|
| Net Preferred Stock Issuance |
|
0.00
|
0.00
+100.00%
|
-9.52
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Payments |
|
0.00
|
0.00
+100.00%
|
-9.52
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-16 View
- 42026-03-17 View
- 42026-03-17 View
- 42026-03-12 View
- 42026-03-12 View
- 42026-03-12 View
- 42026-03-06 View
- 42026-03-06 View
- 42026-03-06 View
- 42026-03-06 View
- 42026-03-06 View
- 8-K2026-02-25 View
- 10-K2026-02-25 View
- 42026-02-18 View
- 8-K2026-01-12 View
- 42025-11-10 View
- 8-K2025-10-29 View
- 10-Q2025-10-29 View
- 8-K2025-09-03 View
- 8-K2025-07-30 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|